Healthcare & Pharmaceuticals
In the final hectic days before Congress adjourns for the year, lobbyists are swarming around the Capitol, trying to adorn a bill on bioterrorism with all sorts of special-interest provisions.
Two years ago, when companies received a big tax break to bring home their offshore profits, the president and Congress justified it as a one-time tax amnesty that would create American jobs. Drug makers were the biggest beneficiaries of the amnesty program, repatriating about $100 billion in foreign profits and paying only minimal taxes. But the companies did not create many jobs in return. Instead, since 2005 the American drug industry has laid off tens of thousands of workers in thi
Johnson & Johnson has been sued by over 1,200 women who blame the company's talcum powder products for their ovarian cancer. Not only are U.S. courts beginning to agree with them, juries have started to award victims millions of dollars in compensation.
U.S. corporations gave away $18.15 billion in charitable donations in 2012 - a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.
A Swiss drug company, Novartis, will go before the Indian Supreme Court this monnth to fight patent laws that protect the global supply of inexpensive medicines to treat AIDS, cancer and other diseases. The lawsuit - which involves a drug called Gleevec - is being opposed by international aid groups.
The HRT (Hormone Replacement Therapy) scandal is bigger than most think. It's not just about menopausal women, like me, getting bad information from their physicians and the pharmaceutical industry for over 40 years, while the federal government stood by and did nothing. The scandal is much bigger than that.
The Kazipally industrial area - once good farm country - now accounts for more than one-third of India's pharmaceutical industry, meaning skyrocketing rates of cancer, heart disease and birth defects for its residents.
DaVita, a company that provides health care to patients with kidney problems, has agreed to pay $495 million to settle whistleblower complaints that the company conspired to overcharge the U.S. government. This is in addition to the $400 million that the company had to pay out last year.